Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224262 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
A Phase 1 study of Influenza, sponsored by Liquidia Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT01224262: Completed Phase 1 study of Influenza, sponsored by Liquidia Technologies.
NCT01224262 is a Phase 1 study of Influenza that has completed, run by Liquidia Technologies. The registered enrollment target is 152 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01224262, a Phase 1 study of Influenza, has completed, sponsored by Liquidia Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the safety, tolerability, and immune response of LIQ001 mixed with a commercially available seasonal influenza vaccine (Fluzone) in two populations of subjects; healthy adult subjects 18 to 49 years of age and healthy elderly subjects 65 years of age or older.
Conditions Studied
Interventions
- BIOLOGICAL Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
- BIOLOGICAL LIQ001 (0.45mg)
- BIOLOGICAL LIQ001 (1.8mg)
Study Locations (1)
Florida
- Accelovance - Melbourne - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT01224262 record still lists
NCT01224262 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) is the first listed.
NCT01224262 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01224262 about?
NCT01224262 is a clinical study titled "A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001". This study is designed to evaluate the safety, tolerability, and immune response of LIQ001 mixed with a commercially available seasonal influenza vaccine (Fluzone) in two populations of subjects; healthy adult subjects 18 to 49 years of age and healthy elderly subjects 65 years of age or older.
What is the current status of trial NCT01224262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2010-09. Estimated completion is 2011-12.
What conditions does trial NCT01224262 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01224262?
The interventions under investigation include: Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) (BIOLOGICAL), LIQ001 (0.45mg) (BIOLOGICAL), LIQ001 (1.8mg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01224262?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01224262 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01224262's enrollment target sits among peer trials
152 89th of 156 higher than 68 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia